S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

NASDAQ:TPTX - Turning Point Therapeutics Stock Price, Forecast & News

$44.66
+0.53 (+1.20 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
$42.49
Now: $44.66
$45.96
50-Day Range
$32.02
MA: $48.68
$66.17
52-Week Range
$24.21
Now: $44.66
$67.54
Volume218,800 shs
Average Volume399,792 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TPTX
CUSIPN/A
CIKN/A
Phone858-926-5251

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$11.28 per share

Profitability

Net Income$-72,130,000.00

Miscellaneous

Employees50
Market Cap$1.60 billion
Next Earnings Date5/29/2020 (Estimated)
OptionableNot Optionable

Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter.


Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

How has Turning Point Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TPTX shares have increased by 10.2% and is now trading at $44.66. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Turning Point Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Turning Point Therapeutics.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 29th 2020. View our earnings forecast for Turning Point Therapeutics.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics (NASDAQ:TPTX) released its earnings results on Monday, March, 16th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.09. View Turning Point Therapeutics' earnings history.

What price target have analysts set for TPTX?

8 brokers have issued 12 month price objectives for Turning Point Therapeutics' stock. Their forecasts range from $48.00 to $72.00. On average, they expect Turning Point Therapeutics' share price to reach $59.25 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price. View analysts' price targets for Turning Point Therapeutics.

Has Turning Point Therapeutics been receiving favorable news coverage?

Headlines about TPTX stock have trended positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Turning Point Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutTurning Point Therapeutics.

Who are some of Turning Point Therapeutics' key competitors?

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include Axsome Therapeutics (AXSM), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Immunomedics (IMMU), Intel (INTC), Sarepta Therapeutics (SRPT), Voyager Therapeutics (VYGR), AbbVie (ABBV), Enterprise Products Partners (EPD) and Energy Transfer LP Unit (ET).

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the following people:
  • Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 47)
  • Dr. Jingrong Jean Cui Ph.D., Scientific Founder, Chief Scientific Officer & Director (Age 55)
  • Mr. Brian L. Baker MS, CPA, VP of Fin. & Admin. (Age 52)
  • Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
  • Ms. Annette C. North, Exec. VP, Gen. Counsel & Company Sec.

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $44.66.

How big of a company is Turning Point Therapeutics?

Turning Point Therapeutics has a market capitalization of $1.60 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe. View additional information about Turning Point Therapeutics.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is http://www.tptherapeutics.com/.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]


MarketBeat Community Rating for Turning Point Therapeutics (NASDAQ TPTX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  74
MarketBeat's community ratings are surveys of what our community members think about Turning Point Therapeutics and other stocks. Vote "Outperform" if you believe TPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: Bollinger Bands

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel